Felypressin
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Sep 20, 2017 (NCT04236115)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Vasopressin V1a receptorACTIVATOR
AVPR1A activator
Chemistry & pharmacology
Loading structure…
SMILES
NCCCC[C@H](CC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O- Mol. weight
- 1039.25 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989781 ↗
- ChEMBLCHEMBL3185126 ↗
- ChEMBLCHEMBL1908309 ↗
Also known as
- felypressin
- felypressin
- octapressin
- octopressin
- phelypressin
- plv-2
- plv-2
- plv-2
- plv-2
- plv-2
- plv-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04236115 | Phase 4 | Sep 20, 2017 | Taibah University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taibah University | Academic/Hospital | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1